drugset / Trial / NCT05967416
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
Non-randomizedSequentialOpen-labelTreatment
Summary
The goal of this study is to test SIRPant-M (RB-1355) , an autologous cell therapy, alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory non-Hodgkin's lymphoma (NHL). Two dose levels of SIRPant-M are being tested. The main question this study aims to answer is if SIRPant-M alone or in combination with radiotherapy is safe and well-tolerated.
Timeline
- Start
- 2024-01-17
- Primary completion
- 2025-06
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SIRPant-M | Cell therapy | 90 cells | Other |
| Subject | SIRPant-M | Cell therapy | 300 cells | Other |
| Subject | SIRPant-M | Cell therapy | 600 cells | Other |